Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Prevention of Staphylococcus epidermidis biofilm formation using electrical current.

Del Pozo JL, Rouse MS, Euba G, Greenwood-Quaintance KE, Mandrekar JN, Steckelberg JM, Patel R.

J Appl Biomater Funct Mater. 2014 Sep 5;12(2):81-3. doi: 10.5301/jabfm.5000208.

2.

The Role of IL-17 in the Association between Pneumococcal Pneumonia and Allergic Sensitization.

Zhao H, Kang CI, Rouse MS, Patel R, Kita H, Juhn YJ.

Int J Microbiol. 2011;2011:709509. doi: 10.1155/2011/709509. Epub 2011 Nov 17.

3.

Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis.

Vergidis P, Rouse MS, Euba G, Karau MJ, Schmidt SM, Mandrekar JN, Steckelberg JM, Patel R.

Antimicrob Agents Chemother. 2011 Mar;55(3):1182-6. doi: 10.1128/AAC.00740-10. Epub 2010 Dec 28.

4.

Are anidulafungin or voriconazole released from polymethylmethacrylate in vitro?

Rouse MS, Heijink A, Steckelberg JM, Patel R.

Clin Orthop Relat Res. 2011 May;469(5):1466-9. doi: 10.1007/s11999-010-1643-7. Epub 2010 Oct 21.

5.

The electricidal effect is active in an experimental model of Staphylococcus epidermidis chronic foreign body osteomyelitis.

Del Pozo JL, Rouse MS, Euba G, Kang CI, Mandrekar JN, Steckelberg JM, Patel R.

Antimicrob Agents Chemother. 2009 Oct;53(10):4064-8. doi: 10.1128/AAC.00432-09. Epub 2009 Aug 3.

6.

Anidulafungin treatment of candidal central nervous system infection in a murine model.

Kang CI, Rouse MS, Mandrekar JN, Steckelberg JM, Patel R.

Antimicrob Agents Chemother. 2009 Aug;53(8):3576-8. doi: 10.1128/AAC.00646-09. Epub 2009 Jun 8.

7.

Species of Propionibacterium and Propionibacterium acnes phylotypes associated with orthopedic implants.

Sampedro MF, Piper KE, McDowell A, Patrick S, Mandrekar JN, Rouse MS, Steckelberg JM, Patel R.

Diagn Microbiol Infect Dis. 2009 Jun;64(2):138-45. doi: 10.1016/j.diagmicrobio.2009.01.024.

PMID:
19505429
8.

Allergic airway inflammation and susceptibility to pneumococcal pneumonia in a murine model with real-time in vivo evaluation.

Kang CI, Rouse MS, Patel R, Kita H, Juhn YJ.

Clin Exp Immunol. 2009 Jun;156(3):552-61. doi: 10.1111/j.1365-2249.2009.03925.x.

9.

Daptomycin in experimental murine pneumococcal meningitis.

Mook-Kanamori BB, Rouse MS, Kang CI, van de Beek D, Steckelberg JM, Patel R.

BMC Infect Dis. 2009 Apr 30;9:50. doi: 10.1186/1471-2334-9-50.

10.

The electricidal effect: reduction of Staphylococcus and pseudomonas biofilms by prolonged exposure to low-intensity electrical current.

del Pozo JL, Rouse MS, Mandrekar JN, Steckelberg JM, Patel R.

Antimicrob Agents Chemother. 2009 Jan;53(1):41-5. doi: 10.1128/AAC.00680-08. Epub 2008 Oct 27.

11.

Bioelectric effect and bacterial biofilms. A systematic review.

Del Pozo JL, Rouse MS, Patel R.

Int J Artif Organs. 2008 Sep;31(9):786-95. Review.

12.

Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.

del Pozo JL, Rouse MS, Mandrekar JN, Sampedro MF, Steckelberg JM, Patel R.

Antimicrob Agents Chemother. 2009 Jan;53(1):35-40. doi: 10.1128/AAC.00237-08. Epub 2008 Aug 25.

13.

Evaluating the role of HLA-DQ polymorphisms on immune response to bacterial superantigens using transgenic mice.

Rajagopalan G, Polich G, Sen MM, Singh M, Epstein BE, Lytle AK, Rouse MS, Patel R, David CS.

Tissue Antigens. 2008 Feb;71(2):135-45. Epub 2007 Dec 13.

PMID:
18086265
14.
15.

Local antibiotic delivery with OsteoSet, DBX, and Collagraft.

Heijink A, Yaszemski MJ, Patel R, Rouse MS, Lewallen DG, Hanssen AD.

Clin Orthop Relat Res. 2006 Oct;451:29-33.

PMID:
16906070
16.

Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model.

Shuford JA, Rouse MS, Piper KE, Steckelberg JM, Patel R.

J Infect Dis. 2006 Sep 1;194(5):710-3. Epub 2006 Jul 28.

PMID:
16897672
17.

Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia.

Rouse MS, Hein MM, Anguita-Alonso P, Steckelberg JM, Patel R.

Diagn Microbiol Infect Dis. 2006 Aug;55(4):333-6. Epub 2006 May 2.

PMID:
16631339
18.

Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.

Anguita-Alonso P, Rouse MS, Piper KE, Steckelberg JM, Patel R.

Antimicrob Agents Chemother. 2006 Apr;50(4):1263-7.

19.

Comparative study of antimicrobial release kinetics from polymethylmethacrylate.

Anguita-Alonso P, Rouse MS, Piper KE, Jacofsky DJ, Osmon DR, Patel R.

Clin Orthop Relat Res. 2006 Apr;445:239-44.

PMID:
16474225
20.

Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis.

Rouse MS, Piper KE, Jacobson M, Jacofsky DJ, Steckelberg JM, Patel R.

J Antimicrob Chemother. 2006 Feb;57(2):301-5. Epub 2005 Dec 16.

PMID:
16361330
21.

In vitro and in vivo evaluations of the activities of lauric acid monoester formulations against Staphylococcus aureus.

Rouse MS, Rotger M, Piper KE, Steckelberg JM, Scholz M, Andrews J, Patel R.

Antimicrob Agents Chemother. 2005 Aug;49(8):3187-91.

22.

Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime.

Alyaseen SA, Piper KE, Rouse MS, Steckelberg JM, Patel R.

Antimicrob Agents Chemother. 2005 Jun;49(6):2543-5.

23.

Release of daptomycin from polymethylmethacrylate beads in a continuous flow chamber.

Hall EW, Rouse MS, Jacofsky DJ, Osmon DR, Hanssen AD, Steckelberg JM, Patel R.

Diagn Microbiol Infect Dis. 2004 Dec;50(4):261-5.

PMID:
15582299
24.

Gentamicin and vancomycin do not impair experimental fracture healing.

Haleem AA, Rouse MS, Lewallen DG, Hanssen AD, Steckelberg JM, Patel R.

Clin Orthop Relat Res. 2004 Oct;(427):22-4.

PMID:
15552131
25.

Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis.

Weaver JG, Rouse MS, Steckelberg JM, Badley AD.

FASEB J. 2004 Aug;18(11):1185-91.

PMID:
15284218
26.

In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria.

Issa NC, Rouse MS, Piper KE, Wilson WR, Steckelberg JM, Patel R.

Diagn Microbiol Infect Dis. 2004 Jan;48(1):73-5.

PMID:
14761726
27.

Levofloxacin and trovafloxacin inhibition of experimental fracture-healing.

Perry AC, Prpa B, Rouse MS, Piper KE, Hanssen AD, Steckelberg JM, Patel R.

Clin Orthop Relat Res. 2003 Sep;(414):95-100.

PMID:
12966282
28.

Antimicrobial release kinetics from polymethylmethacrylate in a novel continuous flow chamber.

Perry AC, Rouse MS, Khaliq Y, Piper KE, Hanssen AD, Osmon DR, Steckelberg JM, Patel R.

Clin Orthop Relat Res. 2002 Oct;(403):49-53.

PMID:
12360007
29.

Reevaluation of Streptococcus bovis endocarditis cases from 1975 to 1985 by 16S ribosomal DNA sequence analysis.

Herrero IA, Rouse MS, Piper KE, Alyaseen SA, Steckelberg JM, Patel R.

J Clin Microbiol. 2002 Oct;40(10):3848-50. Erratum in: J Clin Microbiol. 2003 Feb;41(2):916..

30.

Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis.

Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R.

Clin Infect Dis. 2002 Jun 1;34(11):1469-74. Epub 2002 May 7.

PMID:
12015693
31.

Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis.

Patel R, Rouse MS, Piper KE, Steckelberg JM.

Antimicrob Agents Chemother. 2001 Feb;45(2):621-3.

32.
33.

Linezolid therapy of Staphylococcus aureus experimental osteomyelitis.

Patel R, Piper KE, Rouse MS, Steckelberg JM.

Antimicrob Agents Chemother. 2000 Dec;44(12):3438-40.

34.

Frequency of isolation of Staphylococcus lugdunensis among staphylococcal isolates causing endocarditis: a 20-year experience.

Patel R, Piper KE, Rouse MS, Uhl JR, Cockerill FR 3rd, Steckelberg JM.

J Clin Microbiol. 2000 Nov;38(11):4262-3.

35.

Trovafloxacin treatment of viridans group Streptococcus experimental endocarditis.

Piper KE, Rouse MS, Ronningen KL, Steckelberg JM, Wilson WR, Patel R.

Antimicrob Agents Chemother. 2000 Sep;44(9):2554-6.

36.

Ciprofloxacin inhibition of experimental fracture healing.

Huddleston PM, Steckelberg JM, Hanssen AD, Rouse MS, Bolander ME, Patel R.

J Bone Joint Surg Am. 2000 Feb;82(2):161-73.

PMID:
10682725
37.

Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis.

Patel R, Rouse MS, Florez MV, Piper KE, Cockerill FR, Wilson WR, Steckelberg JM.

J Infect Dis. 2000 Jan;181(1):230-4.

PMID:
10608771
38.
39.

Ketolide treatment of Haemophilus influenzae experimental pneumonia.

Piper KE, Rouse MS, Steckelberg JM, Wilson WR, Patel R.

Antimicrob Agents Chemother. 1999 Mar;43(3):708-10.

40.

Determination of 16S rRNA sequences of enterococci and application to species identification of nonmotile Enterococcus gallinarum isolates.

Patel R, Piper KE, Rouse MS, Steckelberg JM, Uhl JR, Kohner P, Hopkins MK, Cockerill FR 3rd, Kline BC.

J Clin Microbiol. 1998 Nov;36(11):3399-407.

41.

In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.

Patel R, Rouse MS, Piper KE, Cockerill FR 3rd, Steckelberg JM.

Diagn Microbiol Infect Dis. 1998 Feb;30(2):89-92.

PMID:
9554174
42.

Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis.

Rouse MS, Steckelberg JM, Brandt CM, Patel R, Miro JM, Wilson WR.

Antimicrob Agents Chemother. 1997 Aug;41(8):1673-6.

44.

Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents.

Brandt CM, Rouse MS, Laue NW, Stratton CW, Wilson WR, Steckelberg JM.

J Infect Dis. 1996 Apr;173(4):909-13.

PMID:
8603970
45.
46.
47.

Relative efficacies of broad-spectrum cephalosporins for treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis.

Steckelberg JM, Rouse MS, Tallan BM, Osmon DR, Henry NK, Wilson WR.

Antimicrob Agents Chemother. 1993 Mar;37(3):554-8.

48.

Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci.

Hellinger WC, Rouse MS, Rabadan PM, Henry NK, Steckelberg JM, Wilson WR.

Antimicrob Agents Chemother. 1992 Jun;36(6):1272-5.

49.

Animal models as predictors of outcome of therapy with broad spectrum cephalosporins.

Rouse MS, Tallan BM, Henry NK, Steckelberg JM, Wilson WR.

J Antimicrob Chemother. 1992 Apr;29 Suppl A:39-45. Review.

PMID:
1601755
50.

Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits.

Rouse MS, Tallan BM, Steckelberg JM, Henry NK, Wilson WR.

Antimicrob Agents Chemother. 1992 Jan;36(1):56-8.

Supplemental Content

Loading ...
Support Center